Table 4.
Multivariate regression analysis of progression-free survival and overall survival among patients with low-grade and high-grade serous carcinoma
| Prognostic factors | LGSC
|
HGSC
|
||||||
|---|---|---|---|---|---|---|---|---|
| PFS HR (95% CI) |
P-value | OS HR (95% CI) |
P-value | PFS HR (95% CI) |
P-value | OS HR (95% CI) |
P-value | |
| Age | ||||||||
| <50 y | 1.05 (0.59–2.1) | 0.874 | 1.33 (0.57–2.10) | 0.463 | 1.79 (0.63–4.67) | 0.213 | 1.46 (0.83–3.12) | 0.183 |
| ≥50 y | ||||||||
| ECOG score | ||||||||
| 0 | 1.24 (0.76–2.68) | 0.745 | 1.12 (0.64–1.84) | 0.682 | 1.52 (0.51–1.98) | 0.465 | 1.56 (0.82–2.76) | 0.160 |
| ≥1 | ||||||||
| FIGO stage | ||||||||
| I–II | 2.78 (1.64–5.08) | 0.016* | 2.42 (1.24–4.08) | 0.026* | 3.68 (1.89–5.47) | 0.006* | 2.89 (1.54–4.68) | 0.011* |
| III–IV | ||||||||
| Tumor size | ||||||||
| <10 cm | 1.11 (0.78–1.53) | 0.736 | 1.20 (0.72–1.56) | 0.774 | 0.67 (0.27–1.32) | 0.204 | 0.74 (0.35–1.48) | 0.451 |
| ≥10 cm | ||||||||
| Peritoneal cytology | ||||||||
| Negative | 2.66 (1.80–4.62) | 0.012* | 1.74 (0.82–2.54) | 0.257 | 1.43 (0.82–2.35) | 0.564 | 1.24 (0.43–1.90) | 0.712 |
| Positive | ||||||||
| Residual disease | ||||||||
| ≤1 cm | 3.89 (1.75–4.76) | 0.003* | 3.70 (1.56–5.76) | <0.001* | 3.23 (1.63–5.54) | <0.001* | 7.42 (2.68–11.67) | <0.001* |
| >1 cm | ||||||||
Note:
*
Difference reached statistical significance.
Abbreviations: LGSC, low-grade serous carcinoma; HGSC, high-grade serous carcinoma; PFS, progression-free survival; OS, overall survival; ECOG, Eastern Cooperative Oncology Group; FIGO, International Federation of Gynecology and Obstetrics; HR, hazard ratio; CI, confidence interval.